Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2008 2
2009 5
2010 6
2011 4
2012 5
2013 8
2014 10
2015 2
2016 6
2017 9
2018 12
2019 5
2020 3
2021 13
2022 6
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study.
Tangri N, Moriyama T, Schneider MP, Virgitti JB, De Nicola L, Arnold M, Barone S, Peach E, Wittbrodt E, Chen H, Järbrink K, Kushner P. Tangri N, et al. BMJ Open. 2023 May 22;13(5):e067386. doi: 10.1136/bmjopen-2022-067386. BMJ Open. 2023. PMID: 37217263 Free PMC article.
OBJECTIVES: REVEAL-CKD aims to estimate the prevalence of, and factors associated with, undiagnosed stage 3 chronic kidney disease (CKD). DESIGN: Multinational, observational study. ...
OBJECTIVES: REVEAL-CKD aims to estimate the prevalence of, and factors associated with, undiagnosed stage 3 chronic …
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Powell DR, Davies MJ, Banks P, Agarwal R. Cherney DZI, et al. Diabetes Obes Metab. 2023 Jun;25(6):1646-1657. doi: 10.1111/dom.15019. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36782093 Clinical Trial.
AIM: To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2, in adults with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD3). MATERIALS AND METHODS: This phase 3, randomized, …
AIM: To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium-glucose co-transporters 1 and 2, in adults with type 2 d …
Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study.
Tangri N, Peach EJ, Franzén S, Barone S, Kushner PR. Tangri N, et al. Adv Ther. 2023 Jun;40(6):2869-2885. doi: 10.1007/s12325-023-02482-5. Epub 2023 May 3. Adv Ther. 2023. PMID: 37133647 Free PMC article.
However, associations between diagnosis and CKD progression are not fully understood. METHODS: REVEAL-CKD (NCT04847531) is a retrospective observational study of patients with stage 3 CKD. Data were extracted from the US TriNetX database. ...RESULTS: The study included 26, …
However, associations between diagnosis and CKD progression are not fully understood. METHODS: REVEAL-CKD (NCT04847531) is a retrospective …
Lipoprotein(a) in nephrological patients.
Hohenstein B. Hohenstein B. Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):27-30. doi: 10.1007/s11789-017-0086-z. Clin Res Cardiol Suppl. 2017. PMID: 28181057 Free PMC article. Review.
While a number of retrospective and prospective studies suggested that Lp(a) has relevant predictive value and might have - at least in stage-3 chronic kidney disease (CKD) - the same negative effects if draged along in non-CKD patients, …
While a number of retrospective and prospective studies suggested that Lp(a) has relevant predictive value and might have - at least …
Late stage 3 chronic kidney disease is an independent risk factor for sarcopenia, but not proteinuria.
An JN, Kim JK, Lee HS, Kim SG, Kim HJ, Song YR. An JN, et al. Sci Rep. 2021 Sep 16;11(1):18472. doi: 10.1038/s41598-021-97952-7. Sci Rep. 2021. PMID: 34531464 Free PMC article.
A total of 892 outpatients who did not show any rapid changes in renal function were enrolled in this observational cohort study. We measured the muscle mass using bioimpedance analysis and handgrip strength (HGS), and sarcopenia was defined as low HGS and low muscle mass. …
A total of 892 outpatients who did not show any rapid changes in renal function were enrolled in this observational cohort study. We …
Allopurinol Against Progression of Chronic Kidney Disease.
Golmohammadi S, Almasi A, Manouchehri M, Omrani HR, Zandkarimi MR. Golmohammadi S, et al. Iran J Kidney Dis. 2017 Jul;11(4):286-293. Iran J Kidney Dis. 2017. PMID: 28794291 Free article. Clinical Trial.

In patients with severe GFR impairment, serum creatinine levels did not decrease significantly and there was no significant increase in GFR, but in those with mild GFR impairment, serum creatinine levels decreased and GFR increase significantly (P < .001) after administration

…
In patients with severe GFR impairment, serum creatinine levels did not decrease significantly and there was no significant increase in GFR, …
Genetic risk score and risk of stage 3 chronic kidney disease.
Ma J, Yang Q, Hwang SJ, Fox CS, Chu AY. Ma J, et al. BMC Nephrol. 2017 Jan 19;18(1):32. doi: 10.1186/s12882-017-0439-3. BMC Nephrol. 2017. PMID: 28103844 Free PMC article.
BACKGROUND: We developed a genetic risk score (GRS) and examined whether the GRS may predict incident stage 3 chronic kidney disease (CKD) independent of common clinical risk factors. ...CONCLUSIONS: A GRS developed based on 53 SNP …
BACKGROUND: We developed a genetic risk score (GRS) and examined whether the GRS may predict incident stage 3 …
Transformer-based time-to-event prediction for chronic kidney disease deterioration.
Zisser M, Aran D. Zisser M, et al. J Am Med Inform Assoc. 2024 Apr 3;31(4):980-990. doi: 10.1093/jamia/ocae025. J Am Med Inform Assoc. 2024. PMID: 38349850
Performance was evaluated using a real-world claims dataset of over 130 000 individuals with stage 3 chronic kidney disease (CKD). RESULTS: STRAFE showed improved mean absolute error (MAE) compared to other time-to-event algorithms in predict …
Performance was evaluated using a real-world claims dataset of over 130 000 individuals with stage 3 chronic kidney …
Development and Validation of a Chronic Kidney Disease Prediction Model for Type 2 Diabetes Mellitus in Thailand.
Tuntayothin W, Kerr SJ, Boonyakrai C, Udomkarnjananun S, Chukaew S, Sakulbumrungsil R. Tuntayothin W, et al. Value Health Reg Issues. 2021 May;24:157-166. doi: 10.1016/j.vhri.2020.10.006. Epub 2021 Mar 2. Value Health Reg Issues. 2021. PMID: 33662821 Free article.
OBJECTIVES: The objective of this study was to investigate predictors and develop risk equations for stage-3 chronic kidney disease (CKD) in Thai patients with type 2 diabetes mellitus (DM). ...Both models have good discrimination and cal …
OBJECTIVES: The objective of this study was to investigate predictors and develop risk equations for stage-3 chronic …
Premature coronary artery disease and early stage chronic kidney disease.
Price AM, Ferro CJ, Hayer MK, Steeds RP, Edwards NC, Townend JN. Price AM, et al. QJM. 2018 Oct 1;111(10):683-686. doi: 10.1093/qjmed/hcx179. QJM. 2018. PMID: 29024966 Free PMC article. Review.
A 30 year old asymptomatic male with stage 3 chronic kidney disease (CKD) secondary to Focal Segmental Glomerulosclerosis was found to have features of CKD associated cardiomyopathy including left ventricular hypertrophy (LVH) and focal sub-endo …
A 30 year old asymptomatic male with stage 3 chronic kidney disease (CKD) secondary to Focal Segmental Gl …
95 results